• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    AstraZeneca Closes Acquisition of Amolyt Pharma

    GLOBENEWSWIRE

    Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients

    GLOBENEWSWIRE

    Amolyt Pharma Announces Oral Presentation at the 25th ECE 2023

    GLOBENEWSWIRE

    Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

    GLOBENEWSWIRE

    Amolyt Announces Positive Safety and Efficacy Results Pha2a Trial of AZP-3601

    GLOBENEWSWIRE

    Amolyt Pharma Announces +ve Efficacy and Safety Data fromPh 2a Study of AZP-3601

    GLOBENEWSWIRE

    Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Hypoparathyroidism

    GLOBENEWSWIRE

    Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601

    GLOBENEWSWIRE

    Amolyt Pharma Strengthens Leadership Team; Appoints Mark Sumeray as CMO

    GLOBENEWSWIRE

    Amolyt Pharma Announces Positive Results from PIIa Trial of AZP-3601

    GLOBENEWSWIRE

    Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

    GLOBENEWSWIRE

    Amolyt Pharma says US IND Clearance for the Ongoing Trial of AZP-3601

    GLOBENEWSWIRE

    EC Grants ODD to Amolyt Pharma`s AZP-3601 for Hypoparathyroidism

    GLOBENEWSWIRE

    Amolyt Pharma to Participate at Three Upcoming Investor Conferences

    GLOBENEWSWIRE

    Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601

    GLOBENEWSWIRE

    Amolyt Pharma Announces $80 Million Series B Financing

    GLOBENEWSWIRE

    Amolyt Pharma announces USD 80 million Series B financing

    GLOBENEWSWIRE

    Novo-backed Amolyt Pharma snags $80M for endocrine pipeline

    FIERCEBIOTECH

    Amolyt Exercises Option to License Optimized Acromegaly Drug from PeptiDream

    BIOSPACE

    Amolyt Pharma Announces Appointment of Two Directors

    GLOBENEWSWIRE

    Amolyt Pharma Announces Hiring of Louis J. Arcudi III as Chief Financial Officer

    GLOBENEWSWIRE

    Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone

    GLOBENEWSWIRE

    Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.